Fantastic updates about treating intermediate-risk neuroblastoma – St. Baldrick’s Foundation

St. Baldrick’s Foundation shared a post on LinkedIn:

Exciting Update on Neuroblastoma Treatment!

Researchers involved in a St. Baldrick’s supported, Children’s Oncology Group clinical trial have some fantastic updates about treating intermediate-risk neuroblastoma. Here’s the scoop:

What They Did:
They treated 404 kids using a special plan based on the cancer’s biology and how it responded to initial treatment. Initial results already reported excellent 3-year survival. Here are the long-term (10-year) results:

10-Year Event-Free Survival: 82%
10-Year Overall Survival: 95%

Key Takeaway:
The treatment plan from the ANBL0531 COG study shows excellent long-term survival for most kids. However, better treatments are still needed for those with tougher cancer types.”

Additional information
Source: St. Baldrick’s Foundation/LinkedIn